Literature DB >> 12789619

Pralnacasan (vertex pharmaceuticals).

Britta Siegmund1, Martin Zeitz.   

Abstract

Vertex is collaborating with Aventis Pharma AG (formerly Hoechst Marion Roussel Inc) in the development of pralnacasan, an interleukin (IL)-1b converting enzyme (ICE) inhibitor, for the potential treatment of inflammatory diseases [170247], [188293], [453094].

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 12789619

Source DB:  PubMed          Journal:  IDrugs        ISSN： 1369-7056


  12 in total

Review 1.  Development of adjunctive therapies for bacterial meningitis and lessons from knockout mice.

Authors:  Robert Paul; Uwe Koedel; Hans-Walter Pfister
Journal:  Neurocrit Care       Date:  2005       Impact factor: 3.210

Review 2.  Small Molecule Active Site Directed Tools for Studying Human Caspases.

Authors:  Marcin Poreba; Aleksandra Szalek; Paulina Kasperkiewicz; Wioletta Rut; Guy S Salvesen; Marcin Drag
Journal:  Chem Rev       Date:  2015-11-09       Impact factor: 60.622

Review 3.  The potential for caspases in drug discovery.

Authors:  Sarah H MacKenzie; Joshua L Schipper; A Clay Clark
Journal:  Curr Opin Drug Discov Devel       Date:  2010-09

Review 4.  Therapeutics targeting the inflammasome after central nervous system injury.

Authors:  Juan Pablo de Rivero Vaccari; W Dalton Dietrich; Robert W Keane
Journal:  Transl Res       Date:  2015-05-12       Impact factor: 7.012

Review 5.  Pharmacological neuroprotection for glaucoma.

Authors:  Glyn Chidlow; John P M Wood; Robert J Casson
Journal:  Drugs       Date:  2007       Impact factor: 9.546

Review 6.  Caspase substrates and inhibitors.

Authors:  Marcin Poreba; Aleksandra Strózyk; Guy S Salvesen; Marcin Drag
Journal:  Cold Spring Harb Perspect Biol       Date:  2013-08-01       Impact factor: 10.005

Review 7.  Making sense of how HIV kills infected CD4 T cells: implications for HIV cure.

Authors:  Nathan W Cummins; Andrew D Badley
Journal:  Mol Cell Ther       Date:  2014-07-03

Review 8.  A long way to go: caspase inhibitors in clinical use.

Authors:  Shanel Dhani; Yun Zhao; Boris Zhivotovsky
Journal:  Cell Death Dis       Date:  2021-10-15       Impact factor: 8.469

Review 9.  NLRP3 Activation and Its Relationship to Endothelial Dysfunction and Oxidative Stress: Implications for Preeclampsia and Pharmacological Interventions.

Authors:  Priscila Rezeck Nunes; Sarah Viana Mattioli; Valeria Cristina Sandrim
Journal:  Cells       Date:  2021-10-21       Impact factor: 6.600

Review 10.  Pharmacological Inhibitors of the NLRP3 Inflammasome.

Authors:  Ayesha Zahid; Bofeng Li; Arnaud John Kombe Kombe; Tengchuan Jin; Jinhui Tao
Journal:  Front Immunol       Date:  2019-10-25       Impact factor: 7.561
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.